veltcardio2

veltcardio2 t1_jdejmko wrote

Reply to comment by SuppaCoup in Phase 1 study: New medicine extends terminally-ill cancer patients' lives. Seventy percent of the patients who tested the medicine were stable after six weeks. Twelve continued the medication and were stable for 18 weeks. One woman took the medication for 17 months, and was stable for over two years by Wagamaga

Oncologist here. This is a phase 1 trial, it can’t assess efficacy, there is no comparator here. Phase 1 trial exist to asses optimal dosage and safety, side effects, etc. Before it reaches a phase 3 trial (where it would be compared against another established therapy), it needs more testing. It’s too early to even know if it works and even it’s side effects, but it looks like something that should be further studied.

2

veltcardio2 t1_jdeiyq8 wrote

Reply to comment by SaltZookeepergame691 in Phase 1 study: New medicine extends terminally-ill cancer patients' lives. Seventy percent of the patients who tested the medicine were stable after six weeks. Twelve continued the medication and were stable for 18 weeks. One woman took the medication for 17 months, and was stable for over two years by Wagamaga

This is the correct comment. Needs more research and even more trials before efficacy trials. Too early

1

veltcardio2 t1_ita6mlj wrote

Reply to Using a gel-like, radioactive implant, engineers have demonstrated the most effective treatment for pancreatic cancer ever recorded in mouse models, the new treatment completely eliminated tumors in 80 percent of mice across several model types, including those considered the most difficult to treat by giuliomagnifico

Pancreatic cancer death rates are practically unchanged in the last 20 years… it’s probable one of the hardest cancers to treat, aggressive and with an overall survival rate of 5% at 5 years. If you look at other cancers you will see the outlook is way better now, not pancreas. Anyway I hope this goes into clinical trials soon, but the fact remains that we have tried a lot in pancreatic cancer without a lot of luck.

59